Overview

The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The efficacy and safety study of saxagliptin 5mg, once daily for 24 weeks in patients with type 2 diabetes mellitus.
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Saxagliptin